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ABSTRACT The afﬁnity and speciﬁcity of drugs with human serum albumin (HSA) are crucial factors inﬂuencing the bioactivity
of drugs. To gain insight into the carrier function of HSA, the binding of levamlodipine with HSA has been investigated as a model
system by a combined experimental and theoretical/computational approach. The ﬂuorescence properties of HSA and the
binding parameters of levamlodipine indicate that the binding is characterized by one binding site with static quenching mech-
anism, which is related to the energy transfer. As indicated by the thermodynamic analysis, hydrophobic interaction is the
predominant force in levamlodipine-HSA complex, which is in agreement with the computational results. And the hydrogen bonds
can be conﬁrmed by computational approach between levamlodipine and HSA. Compared to predicted binding energies and
binding energy spectra at seven sites on HSA, levamlodipine binding HSA at site I has a high afﬁnity regime and the highest
speciﬁcity characterized by the largest intrinsic speciﬁcity ratio (ISR). The binding characteristics at site I guarantee that drugs
can be carried and released from HSA to carry out their speciﬁc bioactivity. Our concept and quantiﬁcation of speciﬁcity is general
and can be applied to other drug-target binding as well as molecular recognition of peptide-protein, protein-protein, and protein-
DNA interactions.
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Biological function at the molecular level is realized by the
interactions and recognitions among bio-molecules. There
are two crucial factors determining the bio-molecular recog-
nition and binding process. One is the affinity that measures
the stability of associating two molecules together. The other
is the specificity of binding of one molecule with a specific
one but not with others (discriminating against others) (1).
Conventionally, high affinity has been used as the criterion
for the stability and virtual screening of drug targets in the
pharmaceutical industry. However, high affinity fails to
always guarantee high specificity (2), yet high specificity is
crucial for molecular recognition and practice of drug design.
The conventional way of defining specificity is the capa-
bility of discrimination of a specific ligand against different
receptors. To prove the specificity of a ligand to a receptor,
one has to search all the related receptors (Fig. 1 a). This is
not always practical. For a specific ligand binding with
different receptors, we are probing interactions between the
ligand and different receptors through the change of sequences
of the receptors (1,3,4). During the process of a specific ligand
bindingwith a specific receptor, different intermediate binding
modes (states) have different structures and binding energies
with different set of contact interactions between the ligand
and the receptor (Fig. 1 b). By exploring different structures
of various bindingmodes, the binding probes different interac-
tions between the ligand and the receptor. If the receptor is
large and there are sufficient number of contact interactions
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0006-3495/09/05/3917/9 $2.00between the ligand and the receptor, probing interactions
through different structures and sequences should be statisti-
cally equivalent (because exploring different binding struc-
tures mean exploring different spatial contacts and different
contacts explore different sequences). We can therefore
explore the specificity by looking at the different intermediate
bindingmodes between a ligand and a receptor, which ismuch
easier to carry out, rather than looking at the whole universe of
the receptors to test the specificity of a ligand, which is essen-
tially impractical.
The collections of the energies associated with different
intermediate binding modes of a ligand with a receptor form
a binding energy spectrum. The ground state with lowest
energy can be represented as ‘‘native’’ state whereas the pop-
ulation of the rest of the other weakly intermediate bound
states (bindingmodes) is expected to follow aGaussian distri-
bution due to the large number theorem (Fig. 1 c). The two
important energy terms are dE, which represents the energy
gap between the native or lowest energy state and the average
binding energy state, and DE, which defines the energy vari-
ance of the ‘‘nonnative’’ states. The ratio of the two energy
terms dE/DE is defined as the intrinsic specificity ratio
(ISR) (1,4). (Intrinsic specificity here means the capability
of discriminating native binding state (mode) from different
binding states (modes) for a ligand binding with a receptor.)
Because the population follows Boltzmann distribution
P ~ exp[E/kT], a large ISR indicates a high level of discrim-
ination of the minimum energy state (native binding mode)
from the weaker binding states (binding modes) for a partic-
ular ligand-receptor binding complex (Fig. 1 b). From the
discussion on the equivalence of Fig. 1, a and b, the ISR
can serve as a quantitative measure for specificity.
doi: 10.1016/j.bpj.2008.12.3965
Human serum albumin (HSA) as a main carrier protein is
the most abundant in serum and binds many compounds with
high affinity (5). Crystal structure analyses have shown that
HSA has binding sites for compounds at site I and site II in
subdomains IIA and IIIA, respectively. And the sole trypto-
phan residue (Trp214) of HSA is in subdomain II A (6).
Almost all hydrophobic amino acids form hydrophobic cavi-
ties that play an important role on transportation of drugs to
their targets. The previous studies on interactions between
HSA and drugs have provided information of its structural
features, which were based mainly on the size and polarity
rather than affinity and specificity of drugs (7,8). No investi-
gations were made to clarify why site I serves as a primary
binding site for mostly small molecules and why HSA
does possess the carrier function. Thus, the study on the
binding characteristics of drugs to HSA is of importance in
drug research field.
Levamlodipine, S-()-2-[(2-aminoethoxy)methyl]-4-(2-
chlorophenyl)-3-ethoxy-carbonyl-5-methoxycarbonyl-6-
methyl-1,4-dihydropyridine (Fig. 2), is used widely in the
treatment of hypertension and angina (9). So far, very little
knowledge is available about the mode of interaction of
levamlodipine with HSA at molecular level. The occurrence
and nature of levamlodipine binding HSA described in
this study have been investigated as a model system to
FIGURE 1 Illustration of the equivalent concept of the conventional spec-
ificity to intrinsic specificity ratio (ISR) as well as the corresponding energy
spectrum. (a) A specific ligand binding to different receptors, P1–Pn repre-
sent the different proteins with different binding sites. (b) Different binding
modes of a specific ligand to a specific receptor, M1–Mn represent the
different modes with different set of contact interactions. (c) Similar energy
spectrum and the Gaussian distribution, dE represents the energy gap
between the native or lowest energy state and the average binding energy
state, and DE represents the energy variance of the nonnative states.
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affinity and specificity, by a combined experimental and
computational approach. Characterizations of affinity and
specificity may advance our understanding of this unique
carrier protein. The expected output should ultimately help
design levamlodipine derivatives with altered HSA-binding
properties.
MATERIALS AND METHODS
Reagents
HSA was purchased from Sigma Chemical Co. (St. Louis, MO). Levamlo-
dipine was obtained from the National Institute for Control of Pharmaceu-
tical and Products, China. All chemicals were of analytical reagent grade
and MilliQ water was used throughout.
Ultraviolet-vis measurements
Ultraviolet (UV)-vis absorption spectra were recorded on a double beam
Cary 500 Scan UV-vis/NIR spectrophotometer (Varian, Japan) at 298 K
in the range 250–450 nm using a quartz cell with 1.0 cm pathlength.
Fluorescence quenching measurements
Fluorescence measurements were carried out on a laser-induced fluores-
cence spectrofluorimeter equipped with a 150 W xenon lamp and a thermo-
stat bath (PTI, London Ontario, Canada). The excitation wavelength was
290 nm, and the emission spectra were recorded with maximum observed
at 340 nm. Each titration was prepared in a 2 mL quartz cuvette and incu-
bated in dark for 1.0 min. The bandwidth for measuring emission was
5 nm. The temperature of sample was kept by recycled water throughout
experiment.
Theoretical calculations
The possible quenching mechanism between levamlodipine and HSA at
298 K and 309 K can be analyzed by the Stern-Volmer equation (10):
F0=F ¼ 1 þ Kq t0 ½Q; (1)
here F and F0 are the steady state fluorescence intensities in the presence and
absence of quencher, respectively; Kq, t0, and [Q] are the quenching rate
constant, the average lifetime of the molecule without quencher, and the
concentration of quencher, respectively. Taking fluorescence lifetime of
Trp in HSA at ~108 s (11), an approximate quenching rate constant
(Kq, M1 s1) can be obtained by the slope of Stern-Volmer curves.
FIGURE 2 Chemical structure of levamlodipine.
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1) and the number of binding sites n can be
elicited based on the following two equations: (10):
F0=ðF0  FÞ ¼ 1 þ K1A ½Q1; (2)
lg½ðF0  FÞ=F ¼ lg KA þ n lg ½Q: (3)
The thermodynamic parameters were evaluated according to the equation (7):
ln ðKAÞ ¼ DH=ðRTÞ þ DS=R: (4)
Here, R is the gas constant. The free energy change (DG) can be estimated
based on the following typical thermodynamics relationship (7):
DG ¼ DH TDS: (5)
The distance between Trp214 and the bound small molecule can be calculated
according to the Fo¨rster theory (12). The efficiency of energy transfer, E, is
calculated using the following equation:
E ¼ 1 F
F0
¼ R
6
0
R60 þ r6
: (6)
Here, r is the distance between donor and acceptor; R0 is the critical distance
when the transfer efficiency is 50%, which can be calculated by
R60 ¼ 8:8  1025 k2N4FJ; (7)
where K2 is the spatial orientation factor of the dipole; N is the refractive
index of the medium; V is the fluorescence quantum yield of the donor;
and J is the overlap integral of the fluorescence emission spectrum of the
donor and the absorption spectrum of the acceptor. In this case, K2 ¼ 2/3,
N ¼ 1.36, and V ¼ 0.15 (13). J is given by the following equation:
J ¼
P
FðlÞ3ðlÞl4Dl
P
FðlÞDl ; (8)
where F(l) is the fluorescence intensity of the fluorescent donor of wave-
length l; and 3(l) is the molar absorption coefficient of the acceptor at wave-
length l.
Molecular modeling and quantitative measure
of speciﬁcity
Docking calculations were carried out on the system of levamlodipine-HSA
with the Autodock4.0 package (14), which possesses a free-energy scoring
function based on a linear regression analysis. Two parameters, the AMBER
force field and a larger set of diverse protein-ligand complexes with known
inhibition constants, were used in Autodock 4.0. The standard error (SE) is
~2.5 kcal/mol, which is enough to discriminate between leads with milli-,
micro-, and nanomolar inhibition constants. The structure of HSA was ob-
tained from the protein data bank (PDB 1h9z (15)), which has been further
refined and optimized using pdb2pqr1.3 software package (Molecular
Networks GmbH, Germany) to add the missing side chains of some residues
and to remove clashes. The 3D structure of levamlodipine was built by using
the web-tools corina3D. Site I was used as the potential site for target dock-
ing simulations. Autodock tools were used to prepare the protein and the
ligand. All hydrogen atoms were added; and simultaneously, gasteiger
charges were assigned to the protein and the ligand. The nonpolar hydrogen
atoms were merged for the protein and the ligand. The part of myristic acid
retained as a ‘‘plug’’ in the original position was prepared by using the
Chimera package (Molecular Networks GmbH), adding the hydrogen atoms
and the AM1BCC charges (17).
The Autogrid, 60 60 60 grid size, with a spacing of 0.375 A˚ centered
on the special position in the potential binding site was prepared by using
autodock tools. Docking was carried out by using the empirical free energy
function and the Lamarckian genetic algorithm. The molecular modelingwas carried out based on the following parameters: the energy evaluations
of 100,000, the maximum number of 27,000 iterations for an initial
population of 100 randomly placed individuals with a mutation rate of
0.02, a crossover rate of 0.80, and an elitismvalue of 1.0. The other parameters
were defaults. The number of docking runs was 10,000. Evaluation of the
results was carried out by sorting the binding energy predicted by docking
conformations. A cluster of analysis based on the root mean-square deviation
value that is<2.0 A˚ was carried out subsequently. Next, we have investigated
the bindingmodes at the other six binding sites, considering levamlodipine as
the common ligand. All preparations and parameters were consistent with the
contents described as above. For each binding site, we collected different
binding modes with different binding free energy. We can calculate the
affinity, the energy gap between the lowest binding energy state and average
binding energy state as well as the variance of the free energies of different
binding modes. In this way, ISR as the ratio of gap versus square root of vari-
ances of binding energies can be obtained, and the SE is ~0.1.
The resulting seven protein-ligand complexes were subjected to energy
minimization and molecular dynamics (MD). The initial structures were ob-
tained after levamlodipine docking into the structure of HSA as described
above. These structures were prepared using the leap module of Amber 8
(18). The Amber 8 suite of programs together with AMBER FF99 force field
was used to carry out all MD simulations. Each systemwas solvated in a trun-
cated octahedron TIP3P water box (19). Counterions were added to maintain
electroneutrality of the whole system.Minimizations were carried out in three
steps, using the AMBER force field supplemented with parameters for the
nonnatural amino acids. First, holding the protein and ligand fixed, the solvent
molecules were relaxed and optimized, followed by the side chain atoms and
the finally whole protein-ligand complex including the backbone. The MD
was carried out with respect to each system first, applying harmonic restraints
with force constants of 10 kcal/mol/A˚2 to all solute atoms, by heating from
0 to 300 K over 20 ps in the canonical ensemble, followed by equilibrating
to adjust the solvent density under 1 atm pressure over 50 ps in the
isothermal-isobaric ensemble simulation with force constants of 0.5 kcal/
mol/A˚2 to the atoms within 6.0 A˚ from the ligand. The harmonic restraints
were then reduced to zero with 100 ps isothermal-isobaric ensemble simula-
tions for the stability of the whole system. The resulting structures were the
starting points of the production MD simulations. A 1-ns production run
was carried out with the resultant snapshots collected every 1 ps. For all simu-
lations, 2 fs time step and 10 A˚ nonbonded cutoffwere used. The particlemesh
Ewald method (20) was used to treat long-range electrostatics, and bond
lengths involving bonds to hydrogen atoms were constrained by SHAKE
(21). The other parameters were defaults.
Next, we used the trajectories obtained from the above MD simulations,
which was started with the seven complexes to carry out protein-ligand
binding free energy (DG) calculations using the solvated interaction energies
method (22). The binding free energies for the protein-ligand complexes
were estimated using the Sietraj program. Sietraj is an alternative to the
MM-PBSA software provided by the AMBER distribution. It calculates
DG for snapshot structures from the MD simulation with a rigid infinite
separation of the protein and ligand (22).DG is the sum of the intermolecular
van der Waals and Coulomb interactions plus the change in reaction field
energy (determined by solving the Poisson-Boltzmann equation) and
nonpolar salvation energy (proportional to the solvent-accessible surface
area) (22). DG is then scaled by an empirically determined factor, a, ob-
tained by fitting to a training set of 99 protein-ligand complexes. The scaling
can be considered a crude treatment of entropy-enthalpy compensation (22).
The SE is ~0.05.
RESULTS
Characterization of interaction between
levamlodipine and HSA
UV-vis absorption measurement can be used to explore the
complex formation (23). The maximum absorption peak ofBiophysical Journal 96(10) 3917–3925
3920 Liu et al.levamlodipine seems to be 358 nm in ethyl alcohol;
however, it is evident that the UV absorption spectrum of le-
vamlodipine shows a slightly bathochromic shift to 361 nm
and an appreciable enhancement of absorption intensity in
levamlodipine-HSA system (Fig. 3). In this case, the UV
absorption intensity of HSA at 278 nm increases with the
addition of levamlodipine, and simultaneously an appre-
ciable absorbance at 259 nm is observed too. Accordingly,
the absorption intensity increasing of HSA in levamlodi-
pine-HSA system can be interpreted as the result that the
binding of levamlodipine to HSA alters the microenviron-
ment around HSA but not secondary structure (24). In
conclusion, the observation has provided several lines of
evidence in support of the presence of the interaction
between levamlodipine and HSA, and that levamlodipine
accommodates to its binding site on HSA.
HSA shows a characteristic emission maximum at 340 nm
when it is excited at 290 nm, and the single Trp214 residue
can explain the phenomenon (6). The intrinsic fluorescence
of HSA is very sensitive to its microenvironment, namely
when local surrounding of HSA is slightly altered its intrinsic
fluorescence weakens. Thus, the characteristics reflecting
local environmental changes can attribute to HSA conforma-
tion change, bio-molecule binding and denaturation, etc. The
fluorescence quenching of HSA induced by levamlodipine is
displayed in Fig. 4. Obviously, with increasing of the
concentration of levamlodipine the fluorescence intensity
of HSA decreases. An appreciable blue shift from 340 nm
to 332 nm is observed for the maximum emission wave-
length of HSA with progressive titrating levamlodipine
solution to HSA solution. The fluorescence emission wave-
length can be used to estimate the binding mode, because
the wavelength is strongly dependent on the microenviron-
ment especially the hydrophobicity around the protein. The
blue shift of maximum emission wavelength indicates the
FIGURE 3 UV-vis absorption spectra of HSA in the presence of levamlo-
dipine. Curve 1: [levamlodipine] ¼ 1.0  105 M; curve 2: [HSA] ¼ 1.0 
105 M; and curve 3: levamlodipine-HSA complex, [levamlodipine] ¼
[HSA] ¼ 1.0  105 M. T ¼ 298 K, pH ¼ 7.4.Biophysical Journal 96(10) 3917–3925chromophore of protein, Trp214, is placed in a more hydro-
phobic environment after the addition of levamlodipine
(25). Under the experimental temperatures and pH, the
conformation of HSA is not changed (24), and so the dena-
turation can leave out of account. Moreover, the 50 nm of
Dl, the value of difference between excitation and emission
wavelengths, is close to 60 nm that is a characteristic Dl of
the synchronous fluorescence of Trp residue, indicating that
levamlodipine is closed to Trp residue (23). Thus, the strong
fluorescence quenching indicates that levamlodipine binds to
HSA and the binding site is adjacent to the sole tryptophan
residue (25). However, it is worth mentioning that there
are probably other binding modes between them but most
of them are so unstable that they disappear very quickly
and the fluorescence quenching of HSA carries through the
dynamic equilibrium.
Levamlodipine has no fluorescence by fixing the excitation
wavelength at 290 nm, thus, the direct excitation of levamlo-
dipine is avoided at this wavelength. With progressive
increasing concentration of levamlodipine to HSA solution,
the fluorescence intensity of HSA decreases with a regularly
concomitant increase in the levamlodipine emission
(Fig. 5 a). To exclude a false concentration factor and further
to confirm the observed spectral behavior, various concentra-
tions of levamlodipine solution added to PBS buffer without
HSA were used as control samples to monitor spectral
changes. It can be noted that the emission of levamlodipine
in the absence of HSA differs from that in the presence of
HSA (Fig. 5 b), which shows that the increase of levamlodi-
pine emission excited at 374 nm predominantly originates
from the completely HSA-bound levamlodipine. The large
enhancement of the fluorescence emission can be attributed
to the reduced polarity of the environment due to less polar
of the hydrophobic interior of HSA. Thus, the enhancement
FIGURE 4 Fluorescence quenching spectrum of HSA in the presence of
levamlodipine. Concentration of HSA was 2.0  105 M whereas the cor-
responding concentrations of levamlodipine were 0, 4, 12, 20, 24, 32, 40, 50,
60, 70, 80, and 90  106 M, respectively, as the arrow indicates.
T ¼ 298 K; lex ¼ 290 nm; and lem ¼ 340 nm.
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pine in presence of HSA (a, b:) and of alone PBS (b6).
[HSA] ¼ 2.0  105 M; [PBS] ¼ 0.1 M, pH 7.4;
L/P (levamlodipine/HSA molar ratio) from 0.1 to 2.0;
lex ¼ 374 nm.of fluorescence intensity in presence of HSA indicates that
levamlodipine partitions to a restrictive and hydrophobic
binding site in HSA.
Binding mechanism and binding constants
Clearly, the increase of levamlodipine emission is predomi-
nantly attributable to this quenching of Trp fluorescence by
levamlodipine in levamlodipine-HSA system, which is
involved in a fluorescence resonance energy transfer mecha-
nism (12). Fluorescence resonance energy transfer occurs as
long as the fluorescence emission spectrum of fluorophore
(donor) overlaps with the UV absorption spectrum of small
molecule (acceptor). The UV-vis absorption peak of levam-
lodipine is mostly in the range of fluorescence emission
wavelength of HSA (Fig. 6), the fluorescence energy of
HSA therefore can be transferred to levamlodipine. The
calculated distance, r ¼ 4.91 nm, is >8 nm, which agrees
exactly with the nonradiative energy transfer theory (26)
and facilitates the intermolecular energy transfer to the
drug (27). The conclusion can be drawn that the energy
transfer from HSA to levamlodipine occurs and quenches
the florescence of HSA.
For the binding of small molecules to protein, the fluores-
cence measurements can provide some important informa-tion, such as binding mechanism, binding constants, binding
sites, the number of binding sites, etc. As shown in Fig. 7, the
plots show well linear relation at every experimental temper-
ature, which indicates that only one kind of quenching mech-
anisms is predominant, either dynamic one or static one (28).
The corresponding constants of Kq are found to be 4.42 
1011 M1 s1 (r ¼ 0.999) at 298 K and 1.2  1012 M1 s1
(r ¼ 0.998) at 309 K, respectively. The maximum scatter
collision quenching constant Kq of various quenchers for
biopolymers is ~2.0  1010 M1 s1 (29). In this study,
Kq of binding of levamlodipine with HSA is greater than
the maximum value of collision quenching Kq, which means
that the quenching is not initiated by dynamic collision but
by static one, i.e., the formation of levamlodipine-HSA
complex.
The binding constant KA at various temperatures can be
obtained from Fig. 8: KA ¼ 4.3  103 M1 (r ¼ 0.996) at
298 K and KA ¼ 1.2  104 M1 (r ¼ 0.998) at 309 K.
The linearity of both the curves indicates that levamlodipine
binds independently to one class of sites on HSA. The values
of n are noticed to be (1.02  0.01) at 298 K and (0.91 
0.02) at 309 K, respectively. From the data of n, it can be
suggested that there is one independent binding site on
HSA for levamlodipine.FIGURE 6 Overlapping of the fluorescence emission spectrum of HSA
(lex ¼ 290 nm) (1) with UV absorption spectrum of levamlodipine (2).
[levamlodipine] ¼ 1.0  105 M, [HSA] ¼ 1.0  105 M, pH ¼ 7.4;
T ¼ 298 K.
FIGURE 7 Stern-Volmer curves for quenching various concentrations of
levamlodipine with HSA at 298 K and 309 K. [HSA] ¼ 2.0  105 M;
lex ¼ 290 nm.Biophysical Journal 96(10) 3917–3925
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and HSA
According to the dependence of binding constants on
temperature, the thermodynamic parameters considered to
be responsible for the formation of the levamlodipine-HSA
complex were analyzed to further analyze the type of inter-
action forces between levamlodipine and HSA. Usually,
the type of interaction forces between small molecules and
macromolecules mainly include hydrogen bonds, van der
Waals forces, electrostatic interactions, and hydrophobic
interactions (30). To estimate the binding mode, the thermo-
dynamic parameters, enthalpy changes (DH), entropy
changes (DS), and free energy changes (DG), are mainly
considered. On the basis of the characteristic signs of the
thermodynamic parameters, positive DH and DS are
frequently taken as evidences for hydrophobic interactions
(31). This attraction of hydrophobic species is known as
hydrophobic bonding or hydrophobic interaction, which
resulted from their unwelcome reception in water. Here,
both the positive values of DH (71.43 kJ mol1) and DS
(309.3 J mol1 K1) listed in Table 1 show that hydrophobic
interaction plays an absolutely key role in the binding of le-
vamlodipine to HSA. Furthermore, it is clear that the binding
of levamlodipine to HSA is an exothermic process accompa-
nied by negative values of DG and a positive value of DS.
Both the negative values of DG at various temperatures
imply the tendency of spontaneous binding of levamlodipine
to HSA. Moreover, it is worth mentioning that contribution
FIGURE 8 Lineweaver-Burk curves for quenching levamlodipine with
HSA at 298 K and 309 K. [HSA] ¼ 2.0  105 M; lex ¼ 290 nm.
TABLE 1 Thermodynamic parameters of binding of
levamlodipine to HSA
T (K) DG (kJ mol1) DH (kJ mol1) DS (J mol1 K1)
298 20.73 71.43 309.30
309 24.13
Biophysical Journal 96(10) 3917–3925to DG arises more from the TDS rather than from DH, so
the binding process is entropy driven.
Molecular modeling of levamlodipine-HSA
complex
In this study, we have shown the validity of the binding of
levamlodipine with HSA in an experimental way. To further
realize the information of levamlodipine binding HSA,
molecular modeling was applied to predict the binding
mode of levamlodipine in HSA. It can be seen that the
entrance of site I, which is surrounded by positively charged
residues such as Arg218, Arg222, Arg257, His242, and Lys199,
is the binding site (Fig. 9). Of interest is the observation that
the A- and B-rings of levamlodipine are practically
nonplanar, ring A rotates vertically around ring B. The
phenyl of Trp214 is vertically close to the hydrophobic part
of A-ring in levamlodipine with 5.61 nm distance, which is
close to the calculated value and means that the fluorescence
energy of Trp can transfer to levamlodipine to bring the
quenching (27). Within 6 A˚ around levamlodipine, the
surrounding microenvironment of levamlodipine in site I is
shown to be rich in nonpolar amino acid residues, such as
Ala215, Ala261, Ala291, Ile264, Ile290, Leu219, Leu238,
Phe223, and Trp214. Accounting for the hydrophobic property
of levamlodipine (insoluble in water), it can be concluded
that hydrophobic force is the major interaction in the binding
between levamlodipine and HSA.
The interaction between ligands and HSA in site I was
dominated by hydrophobic interactions, but there were also
specific interactions (15). The interaction between levamlo-
dipine and HSA is not exclusively hydrophobic in nature
FIGURE 9 Binding modeling of levamlodipine to HSA in the entrance of
site I. The displayed residues are within 6 A˚ around levamlodipine. The
H-bonds are shown by broken line. Levamlodipine is shown as cylinder
model (C, magenta; O, red; H, white; N, blue; and Cl, green).
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ligand playing a role of stabilizing the ligand via H-bonds
(Fig. 9). As shown, Lys199 and Arg257 are found to be impor-
tant in firming the binding environment of the ligand. The
side chain nitrogen atom of Lys199 is in suitable position
to form intermolecular H-bond with the oxygen atom of
5-methoxycarbonyl of levamlodipine. Additionally, the
intermolecular H-bond is also formed between the main
chain carbonyl oxygen of Arg257 and the nitrogen atom
of (2-aminoethoxy) methyl of levamlodipine. However,
H-bonds fail to be found experimentally, which may be ex-
plained as the following deductions. On the one hand, micro-
environment difference surrounding HSA exists in the
binding system between experimental study under physio-
logical conditions and molecular modeling under ideal
conditions. On the other hand, according to the two molec-
ular properties, the role of hydrophobic force is much greater
than that of H-bonds through comparing their contributions
to the binding of levamlodipine with HSA. Accordingly,
this finding not only provides an optimal structural basis to
explain the very efficient fluorescence quenching of HSA
emission in the presence of levamlodipine, but also supple-
ments the formation of intermolecular H-bond that can not
be validated by experimental method.
Comparison of the binding energies
and ISR values at seven sites
To gain insight into the carrier function of HSA in more
detail, the binding energies at seven binding sites were calcu-
lated by computational method. In addition, ISR was used to
represent the specificity of binding between receptors and
ligands. The binding at site 5 is apparently looser than that
at site 7, and the ISR value is much smaller than that at
site 7 (Table 2). Thus, both the two principal findings
strongly suggest that the complex formation between levam-
lodipine and HSA at the site is the most unstable and nonspe-
cific. This further implies that it is impossible for HSA to
bind and carry levamlodipine in the body through using
site 5. For sites 2, 3, and 4, the bindings are slightly tighter,
but the ISR values are apparently smaller than that at site 7.
From the observation, it can be concluded that the complex
formation is tight but not enough specific at site 2, 3, or 4,
which suggests that levamlodipine bound at site 2, 3, or 4
TABLE 2 Comparison of the predicted binding energies and
ISR values at seven sites on HSA
Binding site
Binding energy
(kcal mol1) ISR
1 9.88 3.87
2 8.99 2.60
3 8.52 1.72
4 9.25 1.38
5 6.49 2.72
6 8.00 3.80
7 8.34 4.11is relatively less specific than at site 7 to release from HSA
to plasma.
In the common practice of binding, high affinity is used as
the screening criterion. The affinity, however, may not
always guarantee the specificity. The intrinsic specificity is
often strongly correlated with the structural fit (4), that is
a good measure of the structure specificity. In the high affinity
zone, the small molecules can still have different specificities.
In current report, the binding at site 1 belongs to the high
affinity regime, but the specificity is less than that at site 7.
We will choose the small molecules with both high affinity
and high specificity as the potential good binding. According
to this opinion, the binding of levamlodipine to HSA at site1
is unfeasible to carry out its carrier and transportation func-
tions based on the view of drug efficacy that only portion
of a drug unbound to plasma is generally bioactive. More-
over, in the body, site 1 allows both electrostatic and hydro-
phobic interactions to contribute to the progressive increase
affinity in the presence of fatty acids (32). This suggests
that it is impossible to displace the fatty acid from site 1
because HSA carries ~0.1–2 mol of fatty acid per mol protein
under normal physiological conditions (33).
Simultaneously, drug-binding experiments indicated that
it was possible to displace fatty acids from sites 6 and 7, sug-
gesting that they may be of relatively lower affinity (34),
which was in agreement with our molecular modeling
results. Experimentally, levamlodipine binds to site 7, one
high-affinity site on HSA, with a binding constant of 1.2 
104 M1 under physiological conditions. Although the
binding constant is <3.4  105 M-1 of high-affinity binding
of warfarin, a probe of site I, it is in the range of typical asso-
ciation constants of 104–106 M1. It is possible for high-
affinity levamlodipine binding to site 7 thus because the
in vivo concentration of drugs is always much lower than
that of HSA (35). Comparing of binding energies and ISR
values at sites 6 and 7, it is clear that the affinity at site 6
is close to that at site 7, but the ISR is smaller than that at
site 7. The observation implies that levamlodipine specifi-
cally binds at site 7 rather than site 6 with the high regime.
DISCUSSION
HSA serves as carrier function for many drugs in the body. A
common set of seven binding sites on HSA, site 1 in subdo-
main IB, site 2 in subdomain IA and IIA, sites 3 and 4 in sub-
domain IIIA, site 5 in subdomain IIIB, site 6 in domain II,
and site 7 in subdomain IIA, have been shown (36). To char-
acterize the protein that is responsible for carrying drugs in
more detail, a total of seven binding sites that were docked
by levamlodipine have been analyzed through comparing
their affinity and specificity.
According to the major idea of drug efficacy, both the
sites, sites 6 and 7, can be principal drug-binding sites for le-
vamlodipine. Why, then, is site 7 the primary binding site for
levamlodipine but not site 6 as indicated experimentally inBiophysical Journal 96(10) 3917–3925
3924 Liu et al.FIGURE 10 Comparison of the predicted levamlodipine
energy spectra at seven sites on HSA.this study? To our knowledge, ligands binding to site II, i.e.,
site 6, are often surrounded by negatively charged aromatic
carboxylic acids. However, levamlodipine is a positively
charged compound. Site II seems to be smaller, or less flex-
ible, than site I, thus, it seems to be more restricted than site I
(35). Furthermore, drugs binding to HSA can be modulated
by simultaneous binding of endogenous compounds, such as
fatty acids. From the view of circulation in the body, site 6
has a high affinity for long-chain fatty acids, whereas site 7
seems to be a primary site for short-chain, but not long-chain,
fatty acids. In addition, long-chain fatty acids are normally
most prevalent in the circulation, and they can enhance the
affinity of the protein for certain site I ligands by induction
of conformational changes in the albumin molecule (35).
The medium-chain fatty acids bind with high affinity to
site II, but only bind to site I with low affinity. Therefore
the displacing effect on site I drugs by competition is prob-
ably very small, which further guarantees levamlodipine
smoothly binds HSA at site I rather than site II. At higher
fatty acid concentrations it is suggestive of a low affinity
interaction between fatty acids and site 7 due to the absence
of specific interactions (15). Importantly, at higher drug
concentrations the affinity for fatty acids falls off, which
probably attributes to the direct competition between the
drug and fatty acids (36). These findings further support
the opinion that levamlodipine is preferential to locate in
site 7 rather than site 6 on HSA under physiological condi-
tions, especially in presence of fatty acids.
Of particular importance is the finding in Table 2 that the
affinity at site 7 is in the high regime with the highest spec-
ificity. We believe our new, to our knowledge, intrinsic spec-
ificity definition has the advantages of quickly identifying
and quantifying the specificity of the ligand to the receptorBiophysical Journal 96(10) 3917–3925without going through all the receptors as the conventional
definition of specificity. This gives an absolute measure of
specificity with a dimensionless quantity, ISR, which can
be calculated once the binding spectrum from the collection
of each intermediate binding mode of a ligand and a receptor
is known. The binding spectra can be obtained through
binding/docking and detailed free energy calculation/confor-
mational search (Fig. 10). The binding, at site 7, with a high-
est ISR value of 4.11 displays a mostly lowest binding
energy that is well set apart energetically from the nonnative
binding states, which exhibits a high intrinsic specificity as is
expected for a binding (4). These bindings at other sites but
site 7 have a smaller energy difference between the native
and average nonnative states relative to the spread of the
energy spectrum of nonnative states. In our recent work,
we have suggested that the origin of high intrinsic specificity
seems to be the underlying hydrophobic interactions (4). It
has been observed that hydrophobic interactions dominate
in the levamlodipine-HSA complex experimentally. The
high ISR value obtained from the physical binding spectrum
thus agrees with the experimental conclusion that hydro-
phobic interactions are mainly responsible for the intrinsic
specificity.
In most cases, drug-HSA interactions will significantly
affect the distribution volume and the elimination rate of
drugs as a result of their binding to HSA (5). Only that
portion of a drug-free in plasma can produce pharmacolog-
ical effect through free transferring to the target organ.
Contrary to this, the drug tightly bound to HSA hardly passes
through the blood capillary walls to reach the action site due
to its larger molecular weight. Thus, the drug specifically
bound in site 7 can free release from HSA due to its relatively
low affinity, which further guarantees HSA to server as the
Afﬁnity/Speciﬁcity of HSA/Drug Binding 3925carrier protein. This rational is in agreement with the drug
soaking experiments (36) and further confirms that levamlo-
dipine may be easier to locate and to displace in site I as
shown experimentally in this study.
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